Data Engineering & Clinical Outcomes
Vijay is a data engineer with a computer science background from Purdue University. He currently works at Medidata Solutions, one of the world's leading clinical trials technology platforms, the infrastructure used by pharma and biotech to run the studies that bring new therapies to patients.
He has built in healthcare before. As co-founder of Track My Medicine, Vijay designed and launched a physician-facing dashboard for tracking patient treatment outcomes, securing seed funding, assembling a scientific advisory board, and shipping a live product to clinics across the country. He knows what it takes to earn a clinician's trust.
RosieVaccine exists because Vijay saw a data gap no one was filling: dogs treated with personalized vaccines have no structured system for capturing what happens next. Every case is a dataset. Every outcome, whether response or progression, is signal that could improve the next vaccine. He is building RosieVaccine to capture that data, and to make sure it gets used.
Oncology Science & Medical Access
Adi is a Doctor of Pharmacy with deep specialization in oncology medical affairs at Pfizer, where he serves as a Field Medical Director and Medical Science Liaison in genitourinary cancers, specifically bladder and kidney cancer. In 2025, Pfizer Oncology recognized him as MSL of the Year for his genitourinary therapeutic area, a distinction awarded to the top-performing field medical professional in the division.
His clinical training at Purdue included rotations at Eli Lilly, Humana, and leading hospital systems. Today, Adi bridges complex clinical evidence and real-world medical access, the exact skill set needed to translate RosieVaccine's bioinformatics output into something the veterinary oncology community will trust and adopt.
Adi guides RosieVaccine's medical strategy: how strong binder thresholds translate to clinical relevance, how to structure outcomes data for eventual peer review, and how to build relationships with veterinary oncology practices at scale.
Biomedical Research & Translational Science
Dr. Agarwal is a board-certified plastic surgeon and translational researcher whose work sits precisely at the boundary RosieVaccine occupies: cancer, immunology, and novel therapeutic delivery. He earned his MD from the University of Chicago Pritzker School of Medicine and is currently co-founder of CircuraBio in Boston, developing next-generation tissue repair and regenerative therapies.
His research portfolio is exceptional: he holds an NIH K08 Mentored Research Award (the NIH's flagship early-career research grant), an NIH R21, a Harvard Stem Cell Institute Pilot Grant, a Beal Fellowship, and a Plastic Surgery Foundation Pilot Award. His work spans cell therapy, synthetic biology, and cancer treatment outcomes, the foundational science behind personalized immunotherapy.
He holds a US patent for a therapeutic method in oncology (US10953028B2) and serves on the editorial boards of Plastic and Aesthetic Research and The Breast Journal. At RosieVaccine, Shailesh ensures the science is rigorous, the pipeline outputs are clinically defensible, and the platform is positioned for eventual peer-reviewed publication.
